The Department of Psychiatry has a strong history of extramural funding, especially in the areas of schizophrenia, depression, brain stimulation, and suicide.  We have received about $2,000,000 in direct costs support for our extramural research programs since fiscal year 2013, with the strongest support coming from the NIMH.

Active Extramural Grants in the Department, by topic:

Schizophrenia

A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizoaffective, or Bipolar I Disorder Who are Early in Their Illness
     Alkermes, Inc
     PI: Joseph McEvoy, M.D.

A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
     NARSAD Independent Investigator Grant
     PI: Brian Miller, MD, PhD, MPH

A randomized controlled trial of adjunctive siltuximab in schizophrenia.
     Stanley Medical Research Institute
     PI: Brian Miller, MD, PhD, MPH

Insomnia, Autonomic Dysfunction, and Suicidal Ideation in Schizophrenia
      Augusta University Pilot Study Research Program
      PI: Brian Miller, MD, PhD, MPH

Improving cognition via exercise in schizophrenia
     National Institute of Mental Health (NIMH)
     PI: Joseph McEvoy, MD

A multi-center, randomized, controlled trial of Brexpiprazole for the treatment of co-occurring schizophrenia and substance use disorder
      Otsuka Pharmaceuticals
      PI: Joseph McEvoy, MD

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
     National Institute of Mental Health (NIMH)
     PI: Joseph McEvoy, MD

Observational Study of LAIs in Schizophrenia
     Alkermes, Inc
     PI: Joseph McEvoy, M.D.

Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate the safety and efficacy of BIIB104 in subjects with cognitive impairment associated with schizophrenia
     Biogen MA, Inc.
     PI: Joseph McEvoy, MD

A randomized controlled trial of adjunctive tocilizumab in schizophrenia.
     NARSAD Independent Investigator Grant
     PI: Brian Miller, MD, PhD, MPH

A randomized controlled trial of adjunctive siltuximab in schizophrenia.
     Stanley Medical Research Institute
     PI: Brian Miller, MD, PhD, MPH

Clozapine, Insomnia, Hyperarousal, and Suicide in Schizophrenia
    Augusta University Pilot Study Research Program
    PI: Brian Miller, MD, PhD, MPH

A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early intervention in patients with attenuated psychosis syndrome.
     Boehringer Ingelheim Pharmaceuticals, Inc.
     PI: Joseph McEvoy, MD

Improving cognition via exercise in schizophrenia
     National Institute of Mental Health (NIMH)
     PI: Joseph McEvoy, MD

Metformin and Lorcaserin for weight loss in people with schizophrenia
     National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
     PI: Joseph McEvoy, MD

A phase II, 12-week, randomized, double-blind, placebo-controlled, parallel study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the three dose levels of TAK-831 in adjunctive treatment of adult patients with negative symptoms of schizophrenia
     Millennium Pharmaceuticals, Inc.
     PI: Joseph McEvoy, MD

Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate the safety and efficacy of BIIB104 in subjects with cognitive impairment associated with schizophrenia
     Biogen MA, Inc.
     PI: Joseph McEvoy, MD


Mood Disorders, Suicide and Sleep


Investigation of the Relationship between suicidal ideation and dysfunctional beliefs about sleep.
     PI: W. Vaughn McCall, MD

PCORI/TRD-1511-3327
1.2 calendar months
Patient-Centered Outcomes Research Institute (PCORI)
Augumentation versus Switch: Comparative Research Trial for Antidepressant Incomplete and Non-responders with Treatment Resistant Depression (ASCERTAIN-TRD)
The goal of this randomized clinical trial is to compare the antidepressant effectiveness of switching treatment resistant depressed patients to either a seratonin-norepinephrine reuptake inhibitor, versus add-on aripiprazole, versus rTMS
ClinicalTrials.gov Identifier: NCT029772299
      PI: W. Vaughn McCall, MD

Pilot studies of pupillometry in suicidal and non-suicidal patients
     Augusta University
     PI: W. Vaughn McCall, MD
     Co-investigator: Nagy Youssef, MD

Reducing suicide ideation through insomnia treatment (REST-IT)
     NIH/NIMH
     PI: W. Vaughn McCall, MD
     Co-investigator: Nagy Youssef, MD

Reducing suicidal ideation through treatment of nightmares - PTSD (REST-ON)
     American Foundation of Suicide Prevention
     PI: W. Vaughn McCall, MD
     Co-investigator: Nagy Youssef, MD


Brain stimulation: ECT and rTMS

A randomized double-blind feasibility study comparing mood and cognitive outcomes for depressed patients treated with transcranial magnetic stimulation (TMS) combined with Lumosity cognitive exercises vs. computer game control task.
     PI: Peter B. Rosenquist, MD

The use of paired pulse TMS measures to assess drug effects on Neuronal Excitability in Amyotrophic Lateral Sclerosis.
     PI: Peter B. Rosenquist, MD

Focal Electrically-Administered Seizure Therapy (FEAST): A preliminary study.
     MECTA Corporation
     PI: Peter B. Rosenquist, MD and W. Vaughn McCall, MD

The Randomised Controlled Trial of Frontoparietal and Temporoparietal Electroconvulsive Therapy (ECT) for Severe Depression: The RAFT ECT Study
     Augusta University
     PI: W. Vaughn McCall, MD

Focal Electrically-Administered Seizure Therapy (FEAST) (2-site study)
     Mecta Corporation (ClinicalTrials.gov   Identifier: NCT02535572)
     PI: W. Vaughn McCall, MD
     Co-investigator: Nagy Youssef, MD

RECOVER: A Prospective, Multi-Center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects with Treatment- Resistant Depression
     Augusta University
     PI: W. Vaughn McCall, MD

Augmentation versus Switch: Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD)
     Patient-Centered Outcomes Research Institute (PCOI)
     ClinicalTrials.gov (Identifier: NCT02977299)
     PI: W. Vaughn McCall, MD
     Co-investigator: Peter Rosenquist, MD

Training Psychiatrists, Nurse Practitioners, and Psychologist to Work Collaboratively to Address Rural Behavioral Health Disparities
     Health Resources and Services Administration
     Behavioral Health Workforce Education and Training Program
     PI: Jean Pawl
     Coinvestigator and Course Director: Peter Rosenquist, MD

Measuring Time-Dependent Pupillary Light Reflex Variables
     PI: W. Vaughn McCall, MD

 


Other

Novel statistical approaches to analyzing actigraphy data.
     PI: W. Vaughn McCall, MD

Inflammation and the Metabolic Syndome in Psychosis
    National Institute of Mental Health
    PI: Brian Miller, MD, PhD, MPH

Assessment and outcomes monitoring in psychiatric clinical practice.
     PI: Peter B. Rosenquist, MD

Screening for clozapine-induced myocarditis-A natrualistic observation study.
     PI: Sandarsh Surya, MBBS and Joseph McEvoy, MD

Double-blind, Placebo-controlled, Phase 2 trial to test efficacy and safety of AV-1-1 (L-4-chlorokynurenine) as adjunct to current antidepressant therapy in patients with major depressive disorder (MDD) with an inadequate response to current antidepressants
     VistaGen Therapeutics, Inc.
     PI: W. Vaughn McCall, MD
     Co-investigator: Nagy Youssef, MD

GRISAT Educational Grant (GRU Interprofessional Substance Abuse Training for Health Professions (GRISAT)
     SAMHSA
     PI: W. Vaughn McCall, MD
     Co-investigator: Nagy Youssef, MD

A six-week, randomized, double-blind, placebo-controlled, suvorexant augmentation study of antidepressant treatment of major depressive disorder with residual insomnia
     Merck & Co., Inc/Institute for Advanvced Medical Research
     PI: W. Vaughn McCall, MD
     Co-investigator: Nagy Youssef, MD